WallStreetZenWallStreetZen

NASDAQ: ARAY
Accuray Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their ARAY stock forecasts and price targets.

Forecast return on equity

Is ARAY forecast to generate an efficient return?
Company
25.37%
Industry
21.02%
Market
52.08%
ARAY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ARAY forecast to generate an efficient return on assets?
Company
2.25%
Industry
11.3%
ARAY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ARAY earnings per share forecast

What is ARAY's earnings per share in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.01
Avg 2 year Forecast
$0.11

ARAY revenue forecast

What is ARAY's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$465.2M+8.05%
Avg 2 year Forecast
$492.7M+14.42%
ARAY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ARAY revenue growth forecast

How is ARAY forecast to perform vs Medical Devices companies and vs the US market?
Company
6.97%
Industry
6.83%
Market
8.26%
ARAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARAY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARAY vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
ARAY$1.90N/AN/A
PROF$7.84$12.00+53.06%Strong Buy
SENS$0.37$2.00+444.96%Buy
ELMD$20.50N/AN/A
CVRX$9.25$13.67+47.75%Strong Buy

Accuray Stock Forecast FAQ

What is ARAY's earnings growth forecast for 2025-2026?

(NASDAQ: ARAY) Accuray's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 35.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.02%.

Accuray's earnings in 2024 is -$21,488,000.On average, 2 Wall Street analysts forecast ARAY's earnings for 2025 to be -$992,442, with the lowest ARAY earnings forecast at -$3,969,767, and the highest ARAY earnings forecast at $1,984,883.

In 2026, ARAY is forecast to generate $10,420,638 in earnings, with the lowest earnings forecast at $7,939,534 and the highest earnings forecast at $12,901,742.

If you're new to stock investing, here's how to buy Accuray stock.

What is ARAY's revenue growth forecast for 2025-2026?

(NASDAQ: ARAY) Accuray's forecast annual revenue growth rate of 6.97% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.26%.

Accuray's revenue in 2024 is $430,554,000.On average, 2 Wall Street analysts forecast ARAY's revenue for 2025 to be $46,168,389,280, with the lowest ARAY revenue forecast at $46,108,842,776, and the highest ARAY revenue forecast at $46,227,935,783.

In 2026, ARAY is forecast to generate $48,892,641,828 in revenue, with the lowest revenue forecast at $48,818,208,699 and the highest revenue forecast at $48,967,074,958.

What is ARAY's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: ARAY) forecast ROA is 2.25%, which is lower than the forecast US Medical Devices industry average of 11.3%.

What is ARAY's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: ARAY) Accuray's current Earnings Per Share (EPS) is -$0.22. On average, analysts forecast that ARAY's EPS will be -$0.01 for 2025, with the lowest EPS forecast at -$0.04, and the highest EPS forecast at $0.02. In 2026, ARAY's EPS is forecast to hit $0.11 (min: $0.08, max: $0.13).

What is ARAY's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: ARAY) forecast ROE is 25.37%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.